Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILX-295501 in Refractory Stage III/IV Ovarian Cancer
NCT00005645Phase 2Withdrawn
- Sponsor
- Sanofi
- Start
- May 1999
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of LY-295501 in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Sanofi. Planned start May 1999; status: withdrawn.
02
Drugs
LY-295501
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00005645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005645.